iPSCs are derived from reprogramming adult cells to revert them to a pluripotent state similar to embryonic stem cells.
By generating various cell types from iPSCs and combining them with biomaterials, it is possible to construct three-dimensional tissues or organs. This has significant applications in tissue engineering, such as creating skin substitutes or liver tissue, helping to address organ donor shortages.
Cells derived from the directed differentiation of iPSCs can be used for high-throughput drug screening and toxicology testing. Utilizing iPSCs allows for the generation of large quantities of highly consistent cells, providing stable and reliable models for new drug development, aiding in the identification of effective and safe drugs.
iPSCs can be used to establish cellular models of various human diseases. By obtaining cells from patients and inducing them to become iPSCs, which are then differentiated into relevant cell types, researchers can simulate the occurrence and progression of diseases in vitro. This is significant for studying genetic disorders, neurodegenerative diseases, cardiovascular diseases, and more.
iPSCs hold significant potential in regenerative medicine. By inducing a patient's own cells to generate iPSCs and then differentiating them into the required cell types, damaged tissues can be repaired or replaced. For example, iPSCs can be used to generate cardiomyocytes for heart disease treatment or neurons for spinal cord injury repair.
iPSCs, combined with gene editing technologies (such as CRISPR-Cas9), can be used in gene therapy research. Researchers can edit specific genes in iPSCs to correct genetic defects, then differentiate the corrected cells into the needed cell types for transplantation back into the patient for gene therapy.
Add a footnote if this applies to your business
1/10
Our company offers custom iPSC culture media and specialized differentiation media at approximately 1/3 or 1/2 the price of similar commercial products, along with corresponding technical support services.
Eureka Biotech Inc. utilizes non-integrative reprogramming methods to prepare four proprietary iPSC lines from human dermal fibroblasts, bone marrow-derived mesenchymal stem cells, and adipose-derived stem cells. Our iPSCs are characterized by pluripotency markers and can efficiently differentiate into neurons and are identified by neural markers and cardiomyocytes.
3675 Market Street, STE 200, Philadelphia, Pennsylvania 19104, United States
Open today | 06:00 – 17:00 |
Copyright © 2024 Eureka Biotech - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.